Effects of dual-task exercise combined with mouth rinse and paprika xanthophyll ingestion on cognitive function - Effects of dual-task exercise combined with mouth rinse and paprika xanthophyll ingestion on cognitive function

Start Date23 Aug 2023

Sponsor / Collaborator

Kansai University

JPRN-UMIN000048322

/ RecruitingNot ApplicableIIT

Effect of carbohydrate intake on competitive performance and substrate oxidation of people with spinal cord injury - Effect of carbohydrate intake on competitive performance and substrate oxidation of people with spinal cord injury

Start Date01 Feb 2023

Sponsor / Collaborator

Kansai University

JPRN-UMIN000054101

/ CompletedNot ApplicableIIT

Carbohydrate mouth rinse during physical activity to improve cognitive function: A randomized cross-over trial - Carbohydrate mouth rinse during physical activity to improve cognitive function: A randomized cross-over trial

Start Date22 Jul 2021

Sponsor / Collaborator

Kansai University

100 Clinical Results associated with Kansai University

0 Patents (Medical) associated with Kansai University

16,932

Literatures (Medical) associated with Kansai University

31 Dec 2025·Science and Technology of Advanced Materials

Development and evaluation of a self-assembled nanoparticle-based prodrug for sustained delivery of 4-phenylbutyric acid

Article

Author: Matsui, Hirofumi ; Shashni, Babita ; Maeda, Kikka ; Nagasaki, Yukio

4-Phenylbutyric acid (PBA) is a small molecule with promising therapeutic potential for treating various diseases, including cancer and neurodegenerative disorders, due to its dual ability to reduce endoplasmic reticulum stress and inhibit histone deacetylases. However, its clinical application is hindered by rapid clearance from the body, necessitating frequent dosing that increases the risk of adverse effects. To address these limitations, we developed a nanoparticle-based prodrug (Nano^PBA) utilizing the amphiphilic block copolymer poly(ethylene glycol)-b-poly(vinyl 4-phenylbutyrate) [PEG-b-P(VPBA)]. This system self-assembles into micelles, enabling controlled and sustained PBA delivery. The synthesis and characterization of Nano^PBA revealed its high stability under physiological conditions and enzyme-responsive PBA release. Nano^PBA demonstrated a controlled release profile in vitro, reducing burst release while maintaining therapeutic efficacy. Cytotoxicity assays using normal cell lines, including endothelial cells (BAEC), macrophages (RAW264.7), and rat gastric cells (RGM-1), showed minimal cytotoxic effects compared to the parent low-molecular-weight PBA. Furthermore, in vivo studies conducted in healthy C57BL/6J mice confirmed Nano^PBA's biocompatibility, with no significant adverse effects observed at therapeutic doses ranging from 200 to 500 mg-PBA/kg via oral administration. In conclusion, Nano^PBA offers a controlled release profile, enhanced biocompatibility, and reduced toxicity, addressing the limitations associated with conventional PBA administration. These attributes make Nano^PBA a promising candidate for improving the therapeutic efficacy and safety of PBA in clinical applications, particularly in diseases where maintaining consistent drug levels is crucial for treatment outcomes.

31 Dec 2025·Development Studies Research

Sedentarization of nomadic people and citizens’ perceptions in Djibouti

Author: Omar Ali, Bouh ; Oyama, Shuichi ; Ito, Yutaka ; Yamamoto, Yuki ; May-Cuevas, Sergio Azael ; Shimada, Sawahiko

01 Jun 2025·Colloids and Surfaces B: Biointerfaces

Antibacterial and bactericidal properties of resin nanostructures coated with SiO2 thin films

Article

Author: Ishiguro, Hitoshi ; Ishibashi, Kenta ; Ito, Takeshi ; Kojima, Hiroaki ; Inoue, Gakuto ; Matsushita, Yuito ; Ogawa, Natsuki ; Shimizu, Tomohiro ; Shingubara, Shoso ; Sunada, Kayano ; Zhao, Zihao

Nanotextures exhibit physical antibacterial and bactericidal properties; hence, they have great potential to prevent infection related to bacteria through contact. The surface characteristics of a nanostructure determine its antibacterial and bactericidal activities. In this study, an atomic layer deposition (ALD) was used to prepare nano-level, hard, thin SiO₂ layers on resin nanostructures and their effects were demonstrated through antibacterial and bactericidal tests. The SiO₂-layer-coated resin nanostructure exhibited a water contact angle of 7.2°, dramatically lower than that of the uncoated specimen (130.2°), as well as a three-fold higher local elastic modulus. Further, 10-nm-thin SiO₂-layer-coated nanopillars showed antibacterial and bactericidal effects against E. coli. These results demonstrate that SiO₂ thin layer coating has great potential for improving the antibacterial and bactericidal properties of polymeric nanopillar arrays.

News (Medical) associated with Kansai University

20 Mar 2024

·www.sobi.com

Trade association memberships

To create a bigger impact in our space, we are an active member of international and national trade associations. We believe that collectively such collaborations allow for knowledge and expertise sharing across our industry, to drive change more effectively than any one organisation alone. Country/Region Name of trade association Belgium Belgium Pharmaceutical Industry Association (Pharma.be) Canada BIOTECanada Innovative Medicines Canada (IMC) Life Sciences Ontario (LSO) RAREi (Rare Innovators) China China Alliance for Rare Diseases (CHARD) China National Pharmaceutical Packaging Association (CNPPA) China Quality Association for Pharmaceuticals (CQAP) Croatia Inovativna farmaceutska inicijativa (iF!) Czech Republic Asociace inovativního farmaceutického průmyslu (AIFP) Denmark Ethical Committee for the Pharmaceutical Industry in Denmark (ENLI) Europe European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) Finland Pharmaceutical Industry in Finland Association (PIF) France Association des Affaires Réglementaires (AFAR) Les Entreprises du Médicament (LEEM) Germany Verband Forschender Arzneimittelhersteller e.V. (VFA) Verein Freiwillige Selbstkontrolle für die Arzneimittelindustrie e. V. (FSA) Global Pharmaceutical Supply Chain Initiative (PSCI) Greece Hellenic Association of Pharmaceutical Companies (SFEE) Pharma Innovation Forum (PIF) Hungary Association of Pharmaceutical Manufacturers (AIPM) Italy Italian Association for the Development of Biotechnology (ASSOBIOTEC) Italian Association of Pharma Companies (Farmindustria) Japan Kansai Pharmaceutical Industries Association (KPIA) Latvia Association of Biopharmaceutical Manufacturers in Latvia Luxembourg Innovative Medicines Luxembourg (IML) The Netherlands HollandBIO Vereniging Innovatieve Geneesmiddelen Poland Izba Gospodarcza "FARMACJA POLSKA" Portugal Associação Portuguesa da Indústria Farmacêutica (APIFARMA) Câmara de Comércio Luso-Sueca (CLS) Russia Association of International Pharmaceutical Manufacturers (AIPM) Slovakia The Orphan Platform The Slovak Association of Manufacturers of Orphan Drugs Slovenia FORUM Spain Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (AELMHU) Asociación Nacional Empresarial de la Industria Farmacéutica (Farmaindustria) Sweden Swecare SwedenBIO Trade association for the research-based pharmaceutical industry in Sweden (Lif) Switzerland Rare Disease Action Forum (RDAF) Vereinigung Pharmafirmen in der Schweiz (VIPS) UK & Ireland Ethical Medicines Industry Group (EMIG) The Association of the British Pharmaceutical Industry (ABPI) UK European Medicines Group (EMG) US Massachusetts Biotechnology Council (MassBio) BIOTECanada Innovative Medicines Canada (IMC) Life Sciences Ontario (LSO) RAREi (Rare Innovators) China Alliance for Rare Diseases (CHARD) China National Pharmaceutical Packaging Association (CNPPA) China Quality Association for Pharmaceuticals (CQAP) Inovativna farmaceutska inicijativa (iF!) European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) Pharmaceutical Industry in Finland Association (PIF) Association des Affaires Réglementaires (AFAR) Les Entreprises du Médicament (LEEM) Verband Forschender Arzneimittelhersteller e.V. (VFA) Verein Freiwillige Selbstkontrolle für die Arzneimittelindustrie e. V. (FSA) Hellenic Association of Pharmaceutical Companies (SFEE) Pharma Innovation Forum (PIF) Italian Association for the Development of Biotechnology (ASSOBIOTEC) Italian Association of Pharma Companies (Farmindustria) HollandBIO Vereniging Innovatieve Geneesmiddelen Izba Gospodarcza "FARMACJA POLSKA" Associação Portuguesa da Indústria Farmacêutica (APIFARMA) Câmara de Comércio Luso-Sueca (CLS) Association of International Pharmaceutical Manufacturers (AIPM) The Orphan Platform The Slovak Association of Manufacturers of Orphan Drugs Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (AELMHU) Asociación Nacional Empresarial de la Industria Farmacéutica (Farmaindustria) Swecare SwedenBIO Trade association for the research-based pharmaceutical industry in Sweden (Lif) Rare Disease Action Forum (RDAF) Vereinigung Pharmafirmen in der Schweiz (VIPS) Ethical Medicines Industry Group (EMIG) The Association of the British Pharmaceutical Industry (ABPI) UK European Medicines Group (EMG) Current as of 20.03.2024

Biosimilar

100 Deals associated with Kansai University

100 Translational Medicine associated with Kansai University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KH-259 ( HDAC6 )	Neurodegenerative Diseases More	Preclinical
KF-52 ( PFKM )	Acidosis, Lactic More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis